Latest breakthroughs in cancer research, treatment, and prevention
643 articles
Intratumoral senescent cells shielded by PD-L2 may explain why chemotherapy often falls short — and point to a new combination strategy.
Fusobacterium nucleatum has shifted from suspected bystander to confirmed cancer driver — here's what the science reveals.
New review reveals how cancer biology has fundamentally transformed our understanding of mitochondrial plasticity and its implications beyond oncology.
A phase 1 trial shows Temferon — a gene-engineered stem cell therapy — safely delivers interferon-α into glioblastoma tumors with no dose-limiting toxicities.
Combining CD38 and PD-1 inhibitors produced durable remissions in relapsed NK/T-cell lymphoma, with median response duration exceeding 29 months.
A phase 3 trial finds scheduling immunochemotherapy before 3 PM nearly doubles progression-free and overall survival in NSCLC patients.
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
A CRISPR screen reveals STK40 suppresses anti-tumor immunity in liver cancer — blocking it supercharges immunotherapy response.
A counterintuitive mechanism shows that more NECTIN4 antigen on tumor cells can actually blunt antibody-drug conjugate therapy.
Tumor-infiltrating adipocytes release a lipid metabolite that triggers neutrophil cell death, suppressing CD8+ T cells in pancreatic cancer.
A Nature Medicine study finds pathogenic germline variants in pediatric patients signal elevated cancer risk, reshaping early genetic screening protocols.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
